MedPath

Angiomax

These highlights do not include all the information needed to use ANGIOMAX safely and effectively. See full prescribing information for ANGIOMAX. ANGIOMAX (bivalirudin) for injection, for intravenous useInitial U.S. Approval: 2000

Approved
Approval ID

5f133813-f74e-4508-bc64-debbf104ff1e

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 30, 2019

Manufacturers
FDA

Sandoz Inc

DUNS: 005387188

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

bivalirudin

PRODUCT DETAILS

NDC Product Code0781-3447
Application NumberNDA020873
Marketing CategoryC73594
Route of AdministrationINTRAVENOUS
Effective DateJune 30, 2019
Generic Namebivalirudin

INGREDIENTS (3)

BIVALIRUDINActive
Quantity: 250 mg in 1 1
Code: TN9BEX005G
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Angiomax - FDA Drug Approval Details